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Abstract
Background: The HD-PTP protein has been described as a tumor suppressor candidate and based on its amino acid
sequence, categorized as a classical non-transmembrane protein tyrosine phosphatase (PTP). To date, no HD-PTP
phosphorylated substrate has been identified and controversial results concerning its catalytic activity have been recently
reported.
Methodology and Results: Here we report a rigorous enzymatic analysis demonstrating that the HD-PTP protein does not
harbor tyrosine phosphatase or lipid phosphatase activity using the highly sensitive DiFMUP substrate and a panel of
different phosphatidylinositol phosphates. We found that HD-PTP tyrosine phosphatase inactivity is caused by an
evolutionary conserved amino acid divergence of a key residue located in the HD-PTP phosphatase domain since its back
mutation is sufficient to restore the HD-PTP tyrosine phosphatase activity. Moreover, in agreement with a tumor suppressor
activity, HD-PTP expression leads to colony growth reduction in human cancer cell lines, independently of its catalytic PTP
activity status.
Conclusion: In summary, we demonstrate that HD-PTP is a catalytically inactive protein tyrosine phosphatase. As such, we
identify one residue involved in its inactivation and show that its colony growth reduction activity is independent of its PTP
activity status in human cancer cell lines.
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Introduction
The classical protein tyrosine phosphatase (PTP) family
characterized by a ,280 amino acid domain containing 10
conserved motifs, is divided into transmembrane receptor-like and
intracellular nonreceptor PTPs, [1,2]. PTP motif 9
(VHCSXGXGR[T/S]G) is one of the most conserved sequences
and corresponds to the active site of the enzyme. The cysteine
residue (C) present in this motif is essential for catalytic activity and
its replacement by a serine residue (S) abrogates the activity (C/S
mutant) [1–3].
The HD-PTP protein has been described as a tumor suppressor
candidate since it is encoded by the PTPN23 gene, located on the
3p21.3 tumor suppressor gene cluster frequently deleted in human
kidney, lung, breast and cervical tumors [4–8]. In agreement with
a tumor suppressor function, HD-PTP expression inhibits ras-
mediated transformation of NIH-3T3 cells; this effect is abrogated
by deletion of its PTP domain as well as by incorporation of a C/S
mutation suggesting that HD-PTP catalytic activity regulates this
function [4]. HD-PTP functions in cell migration and endosomal
trafficking were also recently reported but its exact cellular
activities have not been characterized yet [9–12]. Based on its
amino acid sequence, HD-PTP has been classified as a non-
transmembrane PTP [1,2,8]. Importantly, it possesses a 291
amino acids PTP domain which is comprised of 10 PTP motifs
that define this enzyme family. While bacterially expressed HD-
PTP has recently been reported as catalytically inert, mammalian
expressed HD-PTP tyrosine phosphatase activity has been shown
by another group [11,13].
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5105Here we report a detailed and rigorous enzymatic analysis clearly
demonstrating that mammalian expressed HD-PTP catalytic
domain and full-length proteins do not harbor any PTP activity
towards DiFMUP or phosphatidylinositol phosphates in vitro.T h i s
lack of activity is caused by an evolutionary conserved sequence
divergenceofa key non-consensus residue located inits PTP motif 9,
since its back mutation specifically reactivates HD-PTP tyrosine
phosphatase activity against DiFMUP. We also report that the HD-
PTP tyrosine phosphatase activity status does not affect its colony
growth reduction activity in human cancer cell lines.
Materials and Methods
DNA constructs, cloning and site-directed mutagenesis
Human HD-PTP cDNA was kindly provided by Dr. Mamoru
Ouchida (Okayama University, Okayama, Japan) [8]. The cDNA
encoding the full-length protein (human amino acid 1 to 1636) or
the HD-PTP catalytic domain (human amino acids 1169 to 1460)
were amplified by PCR using primers containing an EcoR1 site at
the 59 end and an Xho1 site at the 39 end and were cloned into a
pcDNA3 vector in frame with two Flag epitopes using EcoR1 and
Xho1 enzymes (2XFlag pcDNA3 vector was previously described
[14]). The integrity and the correct insertion of the cDNA were
verified by sequencing. The C1392S, the S1394A and the
C1392S/S1394A mutants were generated by site-directed muta-
genesis with the Quick Change Site-Directed Mutagenesis kit
(Stratagene, La Jolla, CA) according to the manufacturer’s
directions using Flag-HD-PTP full-length and catalytic domain
constructs as templates and modified forward and reverse primers
described in figure S1. The mutations were confirmed by DNA
sequencing. The GST-PTP1B catalytic domain and the GST-
PTEN wild type and C/S constructs have been previously
described [15,16].
Protein expression and purification
HEK 293T cells were maintained in Dulbecco’s modified Eagle
media (DMEM high glucose) supplemented with 10% fetal bovine
serum at 37uC in a 5% CO2 humidified atmosphere. Cells were
transfected with HD-PTP constructs or an empty vector using
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) according
to the manufacturer’s instructions. Expressed proteins (HD-PTP
full-length or catalytic domain) were purified using a Flag
purification system (EZview Red ANTI-FLAG M2 Affinity Gel,
Sigma-Aldrich, St-Louis, MO): Twenty-four hours post-transfec-
tion, cells were harvested, rinsed with phosphate-buffered saline
(PBS) and lysed 15 min on ice with HNMETG buffer (50 mM
Hepes, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10%
glycerol, 1% Triton X-100, 5 mM DTT and 16of the ROCHE
protease inhibitor cocktail). Cell lysates were cleared by centrifu-
gation at 130006g and incubated with Flag beads for 2 hours at
4uC. Beads were washed 3 times with HNMETG containing only
0.1% Triton X-100 and the Flag-HD-PTP protein was eluted 3
times with 150 ng/ml of Flag peptides in phosphate-buffered
saline solution (PBS). Eluted proteins were concentrated using
Microcon centrifugal Filter Devices (Millipore, Bedford, MA) and
quantified using the RC/DC protein assay kit (Bio-Rad, Hercules,
CA). Equal amounts of proteins were loaded on SDS-PAGE gel
and the presence and the purity of the eluted proteins were
evaluated by Coomassie staining and western blot analysis using
anti-Flag M2 antibody (Sigma-Aldrich, St-Louis, MO). The GST-
tagged catalytic domain of PTP1B and GST-PTEN full-length
were purified as described and their expression was evaluated by
Coomassie staining and western blot analysis using anti-GST
antibody, kindly provided by Dr. N. Sonenberg [15,16].
Enzymatic Assays
Tyrosine phosphatase assays were performed at 37u in black
polystyrol 96-well plate using the EnzCheck Phosphatase Assay
Kit (Molecular Probes, Carlsbad, CA) according to the manufac-
turer’s instructions. Briefly, DiFMUP substrate (100 mM final
concentration) was added to assay buffer (50 mM Hepes, 0.1 mg/
ml BSA, 3 mM DTT, pH 6.5) containing 100 to 200 nM of Flag-
HD-PTP proteins or 2 nM of purified GST-PTP1B in a final
volume of 100 ml. The fluorescence emitted at 450 nm by the
hydrolyzed DiFMU fluorogenic product was monitored every
minute for 30 minutes using the Thermo VARIOSKAN fluores-
cence plate reader (excitation at 358 nm and emission at 450 nm)
and was compared to a standard curve. The rate of the reaction
was obtained by dividing the fluorigenic DiFMU produced (pmole)
per time (minutes). When indicated, 10 mM of the PTP inhibitor
sodium orthovanadate (Fisher Scientific, Ottawa, ON) was added
to the buffer [17]. For pH profiling studies, enzymatic reactions
were performed at the indicated pH (ranging from 4 to 8.5) in
buffer containing 50 mM Tris, 50 mM Bis-Tris and 100 mM
sodium acetate to maintain a constant ionic strength as previously
suggested [18]. For kinetic analysis, a constant concentration of
Flag-HD-PTP was added to different concentration of DiFMUP
substrate (final concentration between 0 and 300 mM). The
reaction rates were plotted against the DiFMUP concentration
to obtain the Michaelis-Menten rectangular hyperbola and kinetic
constants (KM,k cat, and kcat/KM) were derived from this hyperbola
using GraphPad Prism software and compared to known
DiFMUP enzymatic parameters of PTP1B, SHP2 and TC-PTP
tyrosine phosphatases [19] [20]. The lipid phosphatase assays were
performed using the Malachite Green Phosphatase Assay Kit
(Echelon) according to the manufacturer’s directives. Briefly, the
assay was performed by incubating 1 mg of HD-PTP catalytic
domain in assay buffer (25 mM Tris-HCl pH 7.4, 140 mM NaCl,
2.7 mM KCl, 10 mM DTT) for 15 min at 37uC with 120 mMo f
phosphatidylinositol phosphate substrate in a total volume of
25 ml. PTEN (250 ng) was used as a positive control. The reaction
was terminated by adding 100 ml of Malachite Green solution, and
incubated 15 min at room temperature to allow color develop-
ment. The absorbance was read at 620 nm using the Thermo
VARIOSKAN fluorescence plate reader.
Colony formation assays
Renal carcinoma cell lines ACHN and 786-0 were maintained
as described for HEK 293T cells and were transfected with an
empty pcDNA3 vector containing a neomycin resistance gene or
with the Flag-HD-PTP constructs as described above. Twenty-
four hours after transfection, cells were trypsinized, plated in
60 mm dishes and selected for 2 weeks using G418. The colonies
obtained were fixed, stained with Giemsa and counted as
described [21]. An aliquot of cells was preserved for protein
expression levels by western blot analysis using anti-Flag (M2)
antibody and anti-actin (AC74, Sigma-Aldrich, St-Louis, MO) was
used as loading control.
Results
HD-PTP tyrosine phosphatase activity
Recombinant full-length PTPs as well as isolated PTP domains
exhibit tyrosine phosphatase activity in vitro against synthetic
substrates and are used to characterize PTP activity [19,20,22].
However, since PTP activity could be regulated by post-
translational modifications that are not present in protein
expressed in bacteria, results depend on the expression system
used [23]. To clarify the conflicting results regarding HD-PTP
HD-PTP: An Inactive PTP
PLoS ONE | www.plosone.org 2 April 2009 | Volume 4 | Issue 4 | e5105catalytic activity, we evaluated the phosphatase activity of the
mammalian expressed wild type versions of either Flag-HD-PTP
full-length (HD: human amino acid 1 to 1636) or catalytic domain
(CD: human amino acids 1169–1460) and compared it to the
potential catalytically inactive mutant versions (C1392S: C/S)
(Fig. 1). The proteins were expressed in HEK 293T cells, purified
and their presence and purity confirmed by Coomassie staining
and western blot analysis using anti-Flag antibody (Fig. 1A). The
HD-PTP enzymatic activity was assayed using the highly sensitive
non-selective fluorogenic substrate 6, 8-Difluoro-4-Methylumbili-
feryl Phosphate (DiFMUP) as previously described [19,20]. The
fluorescence emitted by the dephosphorylation of the substrate was
monitored every minute for 30 minutes (Fig. 1B) and the rate of
the reaction (pmole of DiFMU/min) was derived (Fig. 1C).
Importantly, even though a slight difference between the reaction
rates of the empty vector (EV) and of the wild type constructs (CD-
WT and HD-WT) was observed, the catalytically inactive mutants
(CD-C/S and HD-C/S) displayed a background activity similar to
the WT. This suggests that HD-PTP is catalytically inactive and
that the weak activity detected with these constructs is due to the
presence of small amounts of PTPs that co-purified with HD-PTP.
These data are in agreement with the absence of activity reported
recently using bacterially expressed HD-PTP with a panel of 38
phospho-peptides and the DiFMUP substrate [13].
Alignment of the catalytic domain of HD-PTP with the other
classical PTP sequences highlighted the presence of many
divergences in critically conserved residues [1]. While HD-PTP
harbors the cysteine (C1392 in the human HD-PTP sequence)
which is essential for catalytic activity located in motif 9, the
alanine (absent in the consensus motif but highly conserved in
other PTPs) which is located at the phosphate-binding loop
(residue 1394 in human HD-PTP sequence) is replaced by a serine
(S) (Fig. 2A). This sequence divergence is well preserved among
different HD-PTP orthologues and is likely to inhibit the
enzymatic activity. Indeed, the conserved phosphate-binding loop
serine residue has been suggested to play an essential role in
stabilizing the enzyme-substrate complex (Fig. 2A) [24]. Further-
more, this residue is replaced by aspartic acid (D) in two known
inactive receptor PTPs (PTP IA2 and PTP IA2b). It was reported
that the back mutation of this residue restores PTP activity [24–
26]. To address this possibility, back mutation of this residue
(S1394A: S/A) was generated by site-directed mutagenesis, and its
effect on HD-PTP catalytic activity was assessed (Fig. 2B–D). In
contrast to HD-WT and CD-WT, the S1394A mutants (CD-S/A
and HD-S/A) displayed significant phosphatase activity
(Fig. 2C, D).
Figure 1. HD-PTP is catalytically inactive. A) Flag-HD-PTP catalytic
domain (CD) or full-length protein (HD) wild type (WT) or C1392S (C/S)
or the corresponding empty vector (EV) were expressed in HEK 293T
cells, purified and visualized by Coomassie staining and western blot
analysis using anti-Flag antibody. B) HD-PTP phosphatase activity was
performed using DiFMUP substrate and representative time-course
kinetic curves of hydrolyzed DiFMU fluorescence emission is shown. C)
The average speed of the reactions (Rate) was derived from the kinetic
curves and is expressed as pmole of DiFMU per minute (pmole/min).
Results represent the average of three independent experiments
(+/2SD).
doi:10.1371/journal.pone.0005105.g001
Figure 2. S1394A mutation restores the HD-PTP catalytic
activity. A) Alignment of the PTP motif 9 consensus with HD-PTP
sequences shows an amino acid divergence conserved among species
(human amino acid 1394 is a serine instead of an alanine; boxed). The
essential catalytic cysteine residue (C) is indicated. B) Purified catalytic
domain of HD-PTP (CD) or full-length protein (HD), wild type (WT) or
S1394A (S/A) were visualized by Coomassie staining and western blot
using anti-Flag antibody. C–F) Phosphatase assays were performed at
pH 6.5 (C, D) or at pH values ranging from 4 to 8.5 (D, E) as described in
figure 1. C, E) Representative time-course kinetic curves of hydrolyzed
DiFMU fluorescence emission. D, F) Average speed of the reaction
(Rate) was derived from the kinetic curves and results represent the
average of three independent experiments (+/2SD).
doi:10.1371/journal.pone.0005105.g002
HD-PTP: An Inactive PTP
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type HD-PTP, we performed enzymatic assays in the pH range
between pH 4 to 8.5 using the catalytic domain and compared this
activity to the S/A mutant (Fig. 2E, F). While the CD-S/A mutant
harbored enzymatic activity in the entire pH range tested with an
optimal activity at pH 6.5, the CD-WT was inactive at all pH
values tested demonstrating that the conserved HD-PTP sequence
divergence in the phosphate-binding loop renders HD-PTP
inactive. We also tested the activity of HD-PTP WT and S/A
against p-nitrophenyl phosphate (pNPP), a synthetic substrate
frequently used to evaluate PTP activity. Unfortunately, this
substrate was not sensitive enough to detect HD-PTP catalytic
activity (data not shown).
Inhibition of HD-PTP S/A activity
To confirm the tyrosine phosphatase specificity of the HD-PTP
S/A catalytic activity, we evaluated the capacity of the well-
described PTP inhibitor sodium othovanadate (Van) to inhibit the
CD-S/A activity (Fig. 3 C, D). Our results show that the inhibitor
efficiently abrogates the activity of the HD-PTP S/A mutant as
well as the protein tyrosine phosphatase 1B isolated PTP domain
(PTP1B) used as a control. In addition, we evaluated the effect of a
C1392S (C/S) mutation on the HD-PTP S1394A (S/A) activity
(Fig. 3 E, F). As expected, the mutation of the catalytically essential
cysteine located in the PTP motif 9 abolishes PTP activity of the
S/A mutants, confirming typical tyrosine phosphatase activity.
Enzymatic parameters of HD-PTP S/A
To characterize the PTP activity of the S/A mutants, a detailed
enzyme kinetic characterization was undertaken. The PTP activity
of the S/A mutants (CD or HD) was determined using increasing
concentrations of DiFMUP substrate (between 0 and 300 mM) and
kinetic constants were derived and compared to parameters
previously determined for the catalytic domain of other PTPs
(Table 1). Although kinetic constants depend largely on experi-
mental conditions, our results suggest that HD-PTP S/A affinity
for substrate (KM) is similar compared to that of other PTPs
(PTP1B, SHP2, TC-PTP) however, its catalytic rate (kcat) is lower
resulting in a lower catalytic efficiency (kcat/KM).
Lipid phosphatase activity
HD-PTP has been classified as a tyrosine-specific PTP based on
its amino acid sequence but our results clearly demonstrated that it
does not harbor any tyrosine phosphatase activity against the
synthetic substrates DiFMUP and pNPP or a library of 38
phospho-peptides [13]. Some PTP members of the PTEN and
myotubularin families have evolved to dephosphorylate phospha-
tidylinositol phosphates specifically [2,27]. For example, purified
PTEN specifically catalyzes dephosphorylation of PI(3,4,5)P
substrates [16]. The HD-PTP sequence does not resemble a lipid
phosphatase based on well-described essential residues in PTEN,
however other critical residues have been identified in PTPRQ
[28]. Indeed, the lipid phosphatase activity of PTPRQ appears to
be dependent on a WPE sequence in its PTP motif 8 that differs
from the conserved WPD consensus sequence. Since HD-PTP also
possesses a WPE sequence, we assessed its ability to dephosphor-
ylate phosphatidylinositiol phosphates using a malachite green-
based assay (Fig. 4) However, our results show that unlike wild
type PTEN (WT), HD-PTP is inactive towards PI(3,4,5)P
substrates (Fig. 4A). The lack of HD-PTP lipid phosphatase
activity also is also observed with other phosphatidylinositol
phosphates including PI(3,4)P, PI(3,5)P or PI(3)P (Fig. 4B–D).
HD-PTP effect on colony growth reduction
Previous work has shown that HD-PTP expression inhibits ras-
mediated cell transformation in NIH 3T3 cells and that deletion of
the catalytic domain as well as the C/S mutation abolishes this
property [4]. This result is inconsistent with the catalytic inactivity
of HD-PTP described here. Using a similar approach, we
addressed the effect of HD-PTP S/A mutation in vivo by evaluating
the ability of HD-PTP to inhibit colony growth formation in
human cancer cell lines. In agreement with its kidney tumor
suppressor potential in humans, we recently reported that mouse
HD-PTP is strongly expressed in the epithelial cells of renal
tubules of the kidney cortex (Gingras et al. in press). We chose two
renal carcinoma cell lines (ACHN and 786-0) that originated from
this location in the kidney to address the tumor suppressor
potential of HD-PTP. Cells were transfected with the same
Figure 3. Inhibition of the HD-PTP S/A activity. A) GST-tagged
catalytic domain of PTP1B, used in C and D was expressed in bacteria
and purified as described [15]. The integrity and the purity of the
recombinant protein were visualized by Coomassie staining and
western blot analysis using anti-GST antibody. B) Flag-HD-PTP catalytic
domain (CD) or full-length (HD) proteins bearing the S1394A (S/A) in
combination or not with the C1392S (C/S) mutation were expressed,
purified and visualized as previously described and used in E and F. C,
D) The effect of the tyrosine phosphatase inhibitor sodium orthova-
nadate (Van) on HD-PTP catalytic domain S1394A mutant (CD-S/A) was
assayed. PTP1B was used as a control of the inhibitor. E, F) The effect of
a C1392S mutation on the HD-PTP catalytic domain or full-length
S1392A mutant activity was assayed using DiFMUP phosphatase assay
as described in figure 1. Representative kinetic curves (C, E) and
average rate of reaction derived from three independent experiments
(+/2SD) (D, F) are shown.
doi:10.1371/journal.pone.0005105.g003
HD-PTP: An Inactive PTP
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gene and were selected with a neomycin analog (G418) for 2
weeks. Expression levels of all proteins were comparable using
western blot analysis (Fig. 5A). The number of emerging colonies
was compared with the number of colonies obtained with the
empty vector (EV) control. Results show that HD-PTP expression
leads to a reduction of colony growth formation in both cell lines
(,70% in ACHN and ,40% in 786-0) (Fig. 5B). However, we did
not observe any difference between the WT, the C/S and the S/A
mutant suggesting that the status of the HD-PTP tyrosine
phosphatase activity does not influence its negative effect on
colony growth formation. Strikingly, the expression of a deletion
mutant of HD-PTP, containing the BRO domain but not the HIS
and PTP domains, did not affect colony growth formation. This
suggests that the PTP domain exhibits functional importance as
demonstrated earlier by the NIH3T3 experiments using the rat
orthologue of HD-PTP [4].
Discussion
While HD-PTP has been described as a classical non-
transmembrane PTP based on its amino acid sequence, our
results demonstrate that it is a catalytically inactive tyrosine
phosphatase. Using a similar mammalian expression system, a
recent study reported tyrosine phosphatase activity associated with
wild type HD-PTP which was similar to the background activity
that we detected in our assays [11]. Their results are supported by
the fact that the well described PTP inhibitor sodium orthovana-
date abrogated 60% of this activity. However, these results were
not compared with activities of inactivating mutants (C/S), which
served as controls in our assays. Strikingly, we show that the
catalytically inactive C/S mutant displays the same level of PTP
activity as the wild type protein. Therefore, we are confident that
the low level of PTP activity detected in both studies is due to co-
purification of contaminating phosphatases. In agreement with
results reported here it has been shown recently that bacterially
expressed HD-PTP catalytic domain was inert against a panel of
38 phosphopeptides and DiFMUP substrate [13]. Our data
strongly suggest that HD-PTP is catalytically inactive due to a
conserved non-consensus key amino acid divergence in its PTP
Table 1. Kinetic constants of HD-PTP S/A and other PTPs
using DiFMUP substrate.
KM (mM) kcat (s
21) kcat/KM
HD-PTP CD-S/A 18 0.1 0.3610
4
HD-S/A 28 0.2 0.6610
4
PTP1B Welte et al. 20 17 84610
4
Montalibet et al. 5.5 28 509610
4
SHP2 Welte et al. 104 1.3 1.3610
4
Montalibet et al. 27 12 44610
4
TC-PTP Welte et al. 26 21 79610
4
Montalibet et al. 11 65 591610
4
doi:10.1371/journal.pone.0005105.t001
Figure 4. HD-PTP does not harbor lipid phosphatase activity.
HD-PTP phosphatase activity toward synthetic phosphatidylinositol
phosphate substrates was evaluated using a malachite green-based
assay. The catalytic domain (CD) of HD-PTP wild type (WT), C1392S (C/S)
or S1394A (S/A) were incubated with PI(3,4,5)P (A), PI(3,4)P (B), PI(3,5)P
(C) and PI(3)P (D) and phosphate release was quantified as described in
Materials and Methods. PTEN wild type (WT) and C132S (C/S) purified
proteins were used as controls. Results represent the average of three
independent experiments (+/2SD).
doi:10.1371/journal.pone.0005105.g004
Figure 5. HD-PTP reduces colony growth formation indepen-
dently of its phosphatase activity status. Colony formation assays
were performed in renal cell carcinoma lines (ACHN and 786-0),
transfected with an empty vector (EV) containing a neomycin resistance
gene or expressing Flag-HD-PTP constructs as indicated. The protein
expression levels were analyzed by western blot using anti-Flag
antibody and anti-actin antibody as a loading control (A). B) Colonies
obtained after 2 weeks of G418 selection were fixed, stained and
counted. Results are expressed as the number of colonies relative to the
EV condition and represent the average of independent experiments
(+/2SD), (786-0: n=4, ACHN: n=5). X: untransfected cells.
doi:10.1371/journal.pone.0005105.g005
HD-PTP: An Inactive PTP
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HD-PTP tyrosine phosphatase activity. The importance of this
residue for the tyrosine phosphatase activity has also been reported
for two other receptor-like PTPs [24,29]. Therefore, we propose to
modify the PTP motif 9 consensus by adding the alanine in
position C+2 to the consensus sequence (VHCSAGXGR[T/S]G).
The HD-PTP sequence displays several differences from the PTP
consensusmotifs,thereforeHD-PTPcouldbeinactivatedatmultiple
key positions and it would be interesting to evaluate if other
reconstitutions of PTP consensus motifs could increase the HD-PTP
catalytic efficiency. For example, in the PTP motif 1 (NXXKNRY),
known as a phosphotyrosine recognition loop that restricts the
substrate specificity to tyrosine-phosphorylated peptide, HD-PTP
(YSLKNRH) displays divergences that are also observed in the two
inactive receptor-like PTPs IA2 and IA2b [1]. Another important
alteration with the PTP consensus is located in motif 8
(WPDXGXP), where the aspartic acid (D) is replaced by a glutamic
acid (E) in the HD-PTP sequence [1]. This residue is known as the
general acid catalyst and its replacement by an alanine residue
considerably reduced PTP activity in PTP1B [30]. This alteration is
also present in a number of inactive D2 domains in receptor PTPs.
However, back mutation of this residue (E/D) was not sufficient to
render HD-PTP catalytically active (data not shown).
In order to rationalize the effect of the conserved residue
alterations in HD-PTP, we generated a homology model (Fig. 6A).
In contrast to alanine in that position, Ser1394 in HD-PTP does
not form favorable substrate interactions with the bound
phosphotyrosine. The polar Ser residue may also repel the
substrate phosphate group and affect the nucleophilic nature of the
adjacent catalytic Cys residue. It is also evident that the tyrosine/
histidine (His1223) exchange in the HD-PTP phosphotyrosine
recognition loop results in the loss of p-p stacking interactions with
the substrate. In addition, surface representation of the PTP1B
active site associated with two phosphotyrosine residues (Fig. 6B)
has been compared to a HD-PTP prediction model associated
with one phosphate (Fig. 6C). The surface representation suggests
that like PTP1B, HD-PTP has an open binding pocket in its active
site that may allow phosphate binding.
In addition to the inactive phosphatases IA2 and IA2b, a number
of other proteins possessing inactive PTP domains have been
described. The second PTP domain (D2) of many classical receptor-
like PTPs and the PTP domain of dual-specificity pseudopho-
sphatases of the myotubularin family lack critical residues essential
for their catalytic activity [1,27]. However, the functional role of
these inactive domains is still uncharacterized. Inactivating PTP
mutants have been shown to preserve their capacity to bind
substrates and have been used to trap and identify specific substrates
in cells [31,32]. The inactive catalytic domain of HD-PTP could
therefore act as a phospho-tyrosine binding module, also called
STYX domain, which may control cell signaling pathways by
preventing the dephosphorylation of its binding partners or by
regulating their cellular localization [27,33].
In agreement with a tumor suppressor function, we observed
that HD-PTP expression reduces colony growth formation
independently of its PTP activity. However, expression of a HD-
PTP mutant devoid of HIS and PTP domains did not affect colony
formation suggesting functional importance of the PTP domain.
This was also demonstrated earlier using the rat orthologue of
HD-PTP in ras transformed NIH3T3 cells [4].
Recently, it has been shown that disruption of the fly orthologue
of HD-PTP resulted in a defect in photoreceptor differentiation
regulated by EGFR [4,12]. Strikingly, the re-expression of the WT
and C/S mutant rescued the defect equally well. This data further
substantiates our results that HD-PTP function in cell signaling is
independent of a tyrosine phosphatase activity.
Supporting Information
Figure S1 Primers sequences: Sense primers containing an
EcoR1 site (underlined) and antisense primers containing an Xho1
site (underlined) used to amplified HD-PTP full-length or catalytic
domain only. Sense and antisense primers used for site-directed
mutagenesis of HD-PTP full-length and catalytic domain.
Nucleotide replacements are indicated in bold.
Found at: doi:10.1371/journal.pone.0005105.s001 (7.62 MB TIF)
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Figure 6. Model of the HD-PTP catalytic domain. A) The HD-PTP
homology model was based on the structure of a PTP1B substrate
complex (pdb-code: 1g1h). HD-PTP residues are labeled in black and
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